Fanny O’Brien

2.1k total citations
24 papers, 818 citations indexed

About

Fanny O’Brien is a scholar working on Neurology, Physiology and Molecular Biology. According to data from OpenAlex, Fanny O’Brien has authored 24 papers receiving a total of 818 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Neurology, 6 papers in Physiology and 5 papers in Molecular Biology. Recurrent topics in Fanny O’Brien's work include Myasthenia Gravis and Thymoma (9 papers), Peripheral Neuropathies and Disorders (8 papers) and Lysosomal Storage Disorders Research (5 papers). Fanny O’Brien is often cited by papers focused on Myasthenia Gravis and Thymoma (9 papers), Peripheral Neuropathies and Disorders (8 papers) and Lysosomal Storage Disorders Research (5 papers). Fanny O’Brien collaborates with scholars based in United States, Italy and United Kingdom. Fanny O’Brien's co-authors include James F. Howard, Paul Desrosiers, Sandra L. Blethen, Louis O’Dea, Saiju Jacob, John Vissing, Kenji P. Fujita, Bernard Bénichou, Sunita Goyal and Crystal Sung and has published in prestigious journals such as Neurology, Fertility and Sterility and The American Journal of Surgical Pathology.

In The Last Decade

Fanny O’Brien

23 papers receiving 784 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Fanny O’Brien United States 15 384 193 129 109 100 24 818
Giada Licata Italy 14 134 0.3× 38 0.2× 114 0.9× 24 0.2× 103 1.0× 23 607
Amnon Cohen Italy 11 71 0.2× 96 0.5× 40 0.3× 20 0.2× 28 0.3× 16 745
Manuela Caruso‐Nicoletti Italy 12 41 0.1× 42 0.2× 25 0.2× 70 0.6× 46 0.5× 41 876
Rachel Kalmann Netherlands 15 151 0.4× 69 0.4× 15 0.1× 9 0.1× 524 5.2× 26 766
J. M. Bilbao Canada 17 391 1.0× 171 0.9× 84 0.7× 2 0.0× 95 0.9× 34 813
S Zecca Italy 6 43 0.1× 72 0.4× 41 0.3× 10 0.1× 18 0.2× 6 412
Anne Miller United Kingdom 12 58 0.2× 92 0.5× 6 0.0× 70 0.6× 177 1.8× 28 539
Michele Nicolai Italy 14 40 0.1× 33 0.2× 23 0.2× 51 0.5× 17 0.2× 48 528
Anna Gambini Italy 9 115 0.3× 36 0.2× 41 0.3× 3 0.0× 72 0.7× 24 663
S. Delalande France 11 261 0.7× 363 1.9× 7 0.1× 5 0.0× 307 3.1× 18 738

Countries citing papers authored by Fanny O’Brien

Since Specialization
Citations

This map shows the geographic impact of Fanny O’Brien's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Fanny O’Brien with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Fanny O’Brien more than expected).

Fields of papers citing papers by Fanny O’Brien

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Fanny O’Brien. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Fanny O’Brien. The network helps show where Fanny O’Brien may publish in the future.

Co-authorship network of co-authors of Fanny O’Brien

This figure shows the co-authorship network connecting the top 25 collaborators of Fanny O’Brien. A scholar is included among the top collaborators of Fanny O’Brien based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Fanny O’Brien. Fanny O’Brien is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Siddiqi, Zaeem A., Richard J. Nowak, Tahseen Mozaffar, et al.. (2021). Eculizumab in refractory generalized myasthenia gravis previously treated with rituximab: subgroup analysis of REGAIN and its extension study. Muscle & Nerve. 64(6). 662–669. 13 indexed citations
2.
Howard, James F., et al.. (2021). Long‐term efficacy of eculizumab in refractory generalized myasthenia gravis: responder analyses. Annals of Clinical and Translational Neurology. 8(7). 1398–1407. 31 indexed citations
3.
Nowak, Richard J., Srikanth Muppidi, Said R. Beydoun, et al.. (2020). Concomitant Immunosuppressive Therapy Use in Eculizumab-Treated Adults With Generalized Myasthenia Gravis During the REGAIN Open-Label Extension Study. Frontiers in Neurology. 11. 556104–556104. 25 indexed citations
4.
5.
Mantegazza, Renato, et al.. (2020). Consistent improvement with eculizumab across muscle groups in myasthenia gravis. Annals of Clinical and Translational Neurology. 7(8). 1327–1339. 28 indexed citations
6.
Nowak, Richard J., Srikanth Muppidi, Said R. Beydoun, et al.. (2019). Changes in Concomitant Immunosuppressive Therapy Use During a Phase 3 Open-label Study of Eculizumab in Adults with Generalized Myasthenia Gravis: an Interim Analysis (P5.2-080). Neurology. 92(15_supplement). 1 indexed citations
7.
Muppidi, Srikanth, Kimiaki Utsugisawa, Michael Benatar, et al.. (2019). Long‐term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle & Nerve. 60(1). 14–24. 175 indexed citations
8.
Tackley, George, Fanny O’Brien, João Carlos da Rocha, et al.. (2016). Neuromyelitis optica relapses: Race and rate, immunosuppression and impairment. Multiple Sclerosis and Related Disorders. 7. 21–25. 31 indexed citations
9.
Howard, James F., Miriam Freimer, Fanny O’Brien, et al.. (2016). QMG and MG-ADL correlations: Study of eculizumab treatment of myasthenia gravis. Muscle & Nerve. 56(2). 328–330. 23 indexed citations
10.
Thurberg, Beth L., Melissa Wasserstein, Thomas D. Schiano, et al.. (2012). Liver and Skin Histopathology in Adults With Acid Sphingomyelinase Deficiency (Niemann-Pick Disease Type B). The American Journal of Surgical Pathology. 36(8). 1234–1246. 49 indexed citations
11.
Watt, Torquil, Alessandro P. Burlina, Chiara Cazzorla, et al.. (2010). Agalsidase beta treatment is associated with improved quality of life in patients with Fabry disease: Findings from the Fabry Registry. Genetics in Medicine. 12(11). 703–712. 65 indexed citations
12.
Lukina, Elena, Nora Watman, Elsa Ávila Arreguin, et al.. (2009). 102. Genz-112638, an investigational oral treatment for Gaucher disease type 1: Preliminary Phase 2 clinical trial results. Molecular Genetics and Metabolism. 96(2). S34–S34.
13.
14.
Bénichou, Bernard, Sunita Goyal, Crystal Sung, Andrea M. Norfleet, & Fanny O’Brien. (2008). A retrospective analysis of the potential impact of IgG antibodies to agalsidase β on efficacy during enzyme replacement therapy for Fabry disease. Molecular Genetics and Metabolism. 96(1). 4–12. 86 indexed citations
15.
Kaufmann, Robert A., R.C. Dunn, Graeme J. Hughes, et al.. (2007). Recombinant human luteinizing hormone, lutropin alfa, for the induction of follicular development and pregnancy in profoundly gonadotrophin‐deficient women. Clinical Endocrinology. 67(4). 563–569. 26 indexed citations
16.
Freedman, Mark S., G. Francis, E. A. C. M. Sanders, et al.. (2005). Randomized study of once-weekly interferon β-1a therapy in relapsing multiple sclerosis: three-year data from the OWIMS study. Multiple Sclerosis Journal. 11(1). 41–45. 34 indexed citations
17.
Evans, William J., Donald P. Kotler, Schlomo Staszewski, et al.. (2005). Effect of recombinant human growth hormone on exercise capacity in patients with HIV-associated wasting on HAART.. PubMed. 15(6). 301–3, 306. 2 indexed citations
18.
Desrosiers, Paul, Fanny O’Brien, & Sandra L. Blethen. (2005). Patient outcomes in the GHMonitor: the effect of delivery device on compliance and growth.. PubMed. 2 Suppl 3. 327–31. 74 indexed citations
19.
Blethen, Sandra L., et al.. (2005). An overview of the GHMonitor, a registry of children treated with Saizen somatropin [recombinant hGH for injection].. PubMed. 2 Suppl 3. 324–6. 2 indexed citations
20.
O’Brien, Fanny, et al.. (2001). Objective evidence of LH-dependence in women with profound LH and FSH deficiency.. Fertility and Sterility. 76(3). S208–S208. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Giada Licata Breakdown of academic impact, for papers by Amnon Cohen Breakdown of academic impact, for papers by Manuela Caruso‐Nicoletti Breakdown of academic impact, for papers by Rachel Kalmann Breakdown of academic impact, for papers by J. M. Bilbao Breakdown of academic impact, for papers by S Zecca Breakdown of academic impact, for papers by Anne Miller Breakdown of academic impact, for papers by Michele Nicolai Breakdown of academic impact, for papers by Anna Gambini Breakdown of academic impact, for papers by S. Delalande
Rankless by CCL
2026